BioBook is being deployed across full spectrum of research biology, including discovery biology, worldwide safety sciences, pharmacokinetics dynamics and metabolism, secondary and safety pharmacology
IDBS reports that Pfizer Global R+D has licensed the IDBS BioBook global electronic experiment and study management software.
BioBook is being deployed across the full spectrum of research biology; including discovery biology, worldwide safety sciences, pharmacokinetics dynamics and metabolism, and secondary and safety pharmacology.
Users of BioBook can manage every aspect of their complex late stage research.
As part of the global contract, BioBook will be used across all of Pfizer's research sites worldwide, with IDBS delivering implementation and support services.
From design and set-up through data capture, analysis and graphing to report creation, sign-off and publication - BioBook manages the entire lifecycle of a complex biological experiment in one place.
All data can be easily and securely recorded in a 21 CFR Part 11 compliant environment.
BioBook enables real-time data sharing, analysis and rapid delivery of reports.
BioBook is the leading commercially available solution for complete electronic experiment and study management in a single secure environment.
Over two hundred life science R+D organisations around the world use IDBS enterprise data management solutions to drive their research, including 18 of the top 20 pharmaceutical and biotechnology companies.
